Rare Disease
A Glance at 2025-2026 Flu Seasons
According to the CDC, a look back at April 2026 cumulative reports showed more than 139 pediatric deaths with approximately 250,000 people hospitalized. In simple
The Silent Struggle – Mental Wellness in NF2 Surgery
Merck and Exelixis Team Up to Transform Treatment for High-Risk Colorectal Cancer Patients
Duchenne Muscular Dystrophy: Coping and Caring
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
McCune-Albright Syndrome
Breakthrough Recognition: Atossa’s (Z)-Endoxifen Earns FDA Rare Pediatric Disease Designation for McCune-Albright Syndrome
Atossa Therapeutics Inc. has achieved a significant regulatory milestone with the U.S. Food and Drug Administration’s grant of Rare Pediatric Disease (RPD) designation to (Z)-endoxifen
Acute Myeloid Leukemia
New Hopes for Acute Myeloid Leukemia
An article from University of Michigan highlighted Jolanta Grembecka and her husband Tomasz Cierpicki, both assistant professors in U of M’s Department of Pathology, who
Ehlers-Danlos Syndrome
Buy Art. Fund Science. Change Lives
Milenia Makani is an abstract artist living in London. She lives with Hypermobile Ehlers-Danlos Syndrome (hEDS), and has launched an international art fundraiser to support
Cancer
When Breakthrough Drugs Need a New Home: Inside the Arvinas-Rigel Partnership
What happens when a pharmaceutical first-mover discovers its historic achievement may not be a blockbuster? Arvinas and Pfizer found an answer this week by handing
Parkinson's Disease
Claudine’s Journey with Parkinson’s Disease
What is Parkinson’s Disease – known as PD for short? Parkinson’s Disease was first discovered in 1817 by a British doctor named James Parkinson. From
Bipolar disorder
The Prevalence of Tick Infections in Pediatric Bipolar Disorders
A recent article by Dr. Rosalie Greenberg explores the possible relationship of infections caused by ticks and psychiatric conditions in children, including PANS or PANDA
Epidermolysis Bullosa
Expanding Hope for Rare Skin Disease: CHOP Becomes Sixth Treatment Center for Revolutionary ZEVASKYN Gene Therapy
Abeona Therapeutics Inc. has announced a significant expansion in access to ZEVASKYN, marking the activation of Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified
Duchenne Muscular Dystrophy
Regenxbio Reports Positive Pivotal Data for Gene Therapy RGX-202 in Duchenne Muscular Dystrophy
As reported on PharmaBiz, Regenxbio has announced encouraging topline findings from the pivotal Phase III portion of its ongoing AFFINITY DUCHENNE clinical program evaluating RGX-202,
Sickle Cell Disease
Canadian Biotech Biossil Identifying Potentially Overlooked Drug Candidates
Biossil, based in Toronto and co-founded by Dr. Alexander Mosa (Chair, CSO and co-founder) and Anthony Mouchantaf (CEO and co-founder), is making headway for rare
Rare Disease
Poolbeg Pharma Expands Global IP Position with Canadian Patent for POLB 001 in CRS
As reported on PharmaTimes, Poolbeg Pharma has secured a Canadian patent protecting the use of p38 MAPK inhibitors, including its lead candidate POLB 001, for preventing
Rare Disease
How to Advocate for Yourself During Appointments
Editor’s Note: This story was originally published on Linked-In and is shared with permission by Olga Lucia Torres. She waited an hour and fifteen minutes to
Rare Disease
GLP-1–Based Therapies Linked to Reduced Risk of Sleep Apnea in Obesity
As reported on Healio, emerging real-world evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists—and related dual agonists—may play a significant role in lowering the risk
Leukodystrophy
Connor’s Leukodystrophy Story
I remember the day I realized something was wrong, as clearly as if it happened this past weekend. It was a beautiful morning in June.
Lupus
The Quiet Revolution: When Hospitals Stop Being Your Second Home
Systemic lupus erythematosus punishes patients twice. First comes the disease itself, an autoimmune disorder where the body attacks its own tissues, causing debilitating fatigue, joint
Cholangiocarcinoma
FDA Expands Approval of Bizengri for Ultra-Rare Cholangiocarcinoma Subset
As reported on BioSpace, the U.S. Food and Drug Administration (FDA) has approved Partner Therapeutics’ bispecific antibody Bizengri for adults with cholangiocarcinoma harboring an NRG1
Rare Disease
In Rare Disease Care, Coordination Should Be Common
Editor’s Note: Patient Worthy is honored to share this submission from Katie DiLorenzo, SVP, Patient and Pharmacy Services, PANTHERx® Rare. If you’re living with a
Epidermolysis Bullosa
Solving Cell Therapy’s Dirty Secret: How One Partnership Could Unlock Consistent Treatments
Mesenchymal stromal cells (MSCs) have tantalized the medical world for years. These versatile immune-modulating cells offer genuine hope for diseases ranging from epidermolysis bullosa, a
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
NF refers to a group of genetic conditions that cause tumors to grow on nerves throughout the body. The types of NF include neurofibromatosis type 1 (NF1), and all types of schwannomatosis (SWN), including NF2-related schwannomatosis (NF2-SWN), formerly called neurofibromatosis type 2, or NF2.
NF2-SWN affects about 1 in 25,000 people worldwide. NF2-related schwannomatosis is much less common than NF1. The condition is characterized by the development of benign tumors, called vestibular schwannomas (formerly called acoustic neuromas), on the nerve that carries sound and balance information from the inner ear to the brain (the eighth cranial nerve). These tumors affect both ears, often leading to partial or complete hearing loss.
People with NF2-SWN may also develop other types of benign brain or spinal tumors. The condition can also cause the development of cataracts or other eye findings, potentially compromising vision. Most people develop symptoms in the late teen and early adult years, although about 10% of people develop symptoms during late childhood. (Source: Children's Tumor Foundation)
Share your NF2-SWN story with us here: bit.ly/4dV7gru
#NF2SWN #nf2awarenessday #PatientWorthy
Amyotrophic Lateral Sclerosis (ALS) Awareness Month is a time to amplify voices, honor strength and bring more awareness to the realities of living with ALS. Every shared story, conversation and moment of support helps remind the ALS community they are not alone.
#amyotrophiclateralsclerosis #ALS #ALSawareness #PatientWorthy
Merck and Exelixis Team Up to Transform Treatment for High-Risk Colorectal Cancer Patients bit.ly/4dBbqVQ Read now at PatientWorthy.com
#PatientWorthy #colorectalcancer #keytruda
